Strategic Collaboration Leverages AI to Accelerate Clinical Development

 We’re thrilled to announce a strategic agreement between Bristol Myers Squibb and Nurocor to bring cutting-edge AI innovation to the life sciences industry.

Through this collaboration, Bristol Myers Squibb’s internally developed generative AI solution will be productized by Nurocor and seamlessly integrated into Nurocor Clinical Platform. This next-generation capability—designed to accelerate clinical development while driving greater efficiency, consistency, and automation across the clinical data lifecycle—will be available to the broader pharmaceutical industry later this year.

Product Capabilities

The power of the digital study definition within Nurocor Clinical Platform extends far beyond transforming a paper protocol into a digital asset. Its real impact lies in accelerating clinical trials by enabling the creation of a complete suite of dependent trial documents with a single action. With Nurocor DocGenAI, think: “One protocol. Twenty documents. One click” saving weeks of time.

We’re excited about the transformative potential of this partnership and the breakthroughs being unlocked for the future of clinical trials.

#AI #GenerativeAI #ClinicalTrials #DigitalHealth #LifeSciences #PharmaInnovation #Nurocor #BristolMyersSquibb